Latest News
Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer
13 June 2023
NEW YORK, June 13, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce the appointment of Matthew Davis, MD,...
Media: MS News Today: Microglial activation reduced in 5 of 6 SPMS patients on nasal foralumab
08 June 2023
Reductions in microglial activation have been observed in the brains of five of six patients with nonactive secondary progressive multiple sclerosis (SPMS) who received treatment with Tiziana Life Science’s foralumab nasal spray.
Microglia, resident immune cells in the brain,...
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis
05 June 2023
- Results confirm positive signal previously reported in the first two Expanded Access patients who both subsequently demonstrated clinical improvements
- Phase 2a trial in na-SPMS...
Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS), Webinar to take place on Monday, June 5, 2023 at 12:30 PM ET
25 May 2023
NEW YORK, May 25, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it will host a virtual KOL event...
Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform
23 May 2023
NEW YORK, May 23, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that they are now participating on the new...
Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17
17 May 2023
NEW YORK, May 17, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Medical Officer is presenting at...
Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
27 April 2023
- There are no effective treatments for intracerebral hemorrhage (ICH), which has a 30% to 40% mortality rate
- Intranasal anti-CD3 mAb treatment showed a reduction...
Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update
26 April 2023
NEW YORK, April 26, 2023 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced financial results for the twelve months ended December 31,...
Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
24 April 2023
NEW YORK, April 24, 2023 -- Tiziana Life Sciences Ltd.. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that it has received a notification from the Nasdaq...
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023
20 April 2023
- Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023
- Tiziana guided by FDA Type “B” meeting...